Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models
- 1 June 2002
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (12) , 759-768
- https://doi.org/10.1038/sj.gt.3301698
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 35 references indexed in Scilit:
- A Tissue-Specific Enhancer of the Prostate-Specific Membrane Antigen Gene, FOLH1Genomics, 2001
- Radical Prostatectomy versus Brachytherapy for Early-Stage Prostate CancerJournal of Endourology, 2000
- Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenovirusesHepatology, 1998
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus disseminationGene Therapy, 1997
- In VivoGene Therapy of Cancer withE. coliPurine Nucleoside PhosphorylaseHuman Gene Therapy, 1997
- Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 1997
- Stereoselective Synthesis of 6-Methyl-9-(2-Deoxy-β-D-Erythro-Pentofuranosyl)purineNucleosides and Nucleotides, 1996
- Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed by Ganciclovir in Mouse and Human Prostate Cancer ModelsHuman Gene Therapy, 1996
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996